Related by context. All words. (Click for frequent words.) 74 submitted Biologics License 73 rolling Biologics License 69 submitted Marketing Authorization 69 submitted Marketing Authorisation 67 Files IND 66 Submits Supplemental 66 Files Investigational 65 neuromodulation therapy 65 Application BLA 64 Biologic License Application BLA 63 Premarket Approval PMA 63 IND Investigational New 63 supplemental biologics 62 Kobo Desktop 62 Premarket Approval 62 BLA filing 61 Marketing Authorisation 61 Biologics Licensing 61 Biological License Application 61 Voraxaze 61 Biologic License Application 61 Nabi HB Intravenous 61 Submits NDA 61 Initiates Clinical 61 Submits IND 60 FDA Accepts 60 Receives CE Marking 60 M Enoxaparin 60 Completes Patient Enrollment 60 Submits Investigational 60 SYCREST 60 Ready Templates 60 ENTEREG ® 60 Submits Response 60 Resubmission 60 Accelerated Approval 60 Marketing Approval PMA 60 Luveniq 60 Initiates Phase II 60 Biologics License Application BLA 60 Begins Dosing 59 Initiates Enrollment 59 Initiate Clinical Trial 59 Somatuline R Autogel R 59 liver resection surgeries 59 Initiates Phase III 59 NASDAQ BDSI 59 NDA Submission 59 LUCASSIN 59 JOULFERON 59 Submits Biologics License Application 59 CIP TRAMADOL ER 59 Civacir 59 initiate Phase Ib 59 Japanese Encephalitis Vaccine 59 Marketing Authorisation Application 59 GTC recombinant form 59 Initiate Phase 59 initiate Phase IIb 58 Phase III Pivotal 58 PDUFA Date 58 Act PDUFA date 58 Bioral Amphotericin B 58 Submits Application 58 NasdaqGM NTEC today 58 Receives Orphan Drug Designation 58 initiated Phase Ib 58 Issued Patent 58 IND Filing 58 successfully commercialize Iluvien 58 Marketing Authorization Application 58 Receives NASDAQ 58 Receive Milestone Payment 58 Receives Orphan Drug 58 Granted Orphan Drug 58 Receives Tentative FDA 58 Presents Positive Preclinical 58 submitted supplemental Biologics 58 BioDelivery Sciences Announces 58 Orathecin 58 KRYSTEXXA TM pegloticase 58 IDE Investigational Device Exemption 58 supplemental Biologics License Application 58 Patient Enrolment 58 Biologics License Application 58 Qutenza TM 57 StaphVAX R 57 InterfeRx 57 Loramyc TM 57 Esbriet pirfenidone 57 PRECISE Trial 57 Zenvia ™ 57 ACCLAIM II 57 AIMM trial 57 Approves Stock Repurchase 57 OLEPTRO 57 trastuzumab DM1 T DM1 57 Fast Track Status 57 Surfaxin LS 57 License Application sBLA 57 Orphan Drug designations 57 Resubmit 57 VIVITROL ® 57 PREOS R 57 Therapeutic Competitors Companies 57 Investigational Device Exemption 57 PROVENGE ® 57 BRILINTA 57 Aloxi Injection 57 k Premarket Notification 57 Receives Approvable Letter 57 Premarket Notification 57 sNDAs 57 please visit http:/www.sunesis.com 57 Phase #b/#a clinical 57 OLpur TM H2H 57 MOVIPREP R 57 Biophan patent 57 Approves Share Repurchase 57 highly purified pasteurized 57 FDA Approvable Letter 57 Expedited Review 57 IND submission 57 NASDAQ PGNX 57 Angiox ® 57 Conditional Approval 57 JZP 57 Personalized Immunotherapy 57 JAK2 Inhibitor 56 MAA submission 56 Zenpep 56 Files Provisional 56 OMAPRO ™ 56 ARRY # 56 novel MetAP 2 56 Phase Ib study 56 CRMD# 56 PMA submission 56 No. #.# 56 assigned PDUFA 56 Valortim TM 56 Centralized Procedure 56 hoFH 56 Application MAA 56 RIGScan CR 56 Resubmits 56 vinorelbine emulsion 56 Cutanea Life Sciences 56 euro adhoc Intercell AG 56 Pivotal Phase III 56 Phase III Clinical Trial 56 Initiates Clinical Trial 56 Acetavance TM 56 RANK Ligand inhibitor 56 NUEDEXTA ™ 56 Soliris eculizumab 56 markets HP Acthar 56 Orphan Status 56 Flutiform ™ 56 Increlex TM 56 TAXUS Element Stent System 56 Premarket Approval Application 56 Patient Enrollment 56 LEVADEX TM 56 CAP ROE 56 Kuvan R 56 Marketing Authorisation Application MAA 56 Marketing Authorization Application MAA 56 Reexamination Certificate 56 molecular imaging radiopharmaceutical 56 CONBRIZA 56 Risperidone Oral Solution 56 Supplemental Biologics License Application 56 Commence Phase 56 Allovectin 7 r 56 Loramyc R 56 Awarded Qualifying Therapeutic 56 Gets FDA Clearance 56 Fast Track designations 56 Presents Preclinical 56 Exploratory IND 56 Reports Preclinical Data 56 Nasdaq DVAX 56 initiate Phase IIa 56 PF # [002] 56 SURFAXIN 56 Grants Orphan Drug 56 Psoriasis Drug 56 BLA submission 56 R MSCRAMM 56 Receives Milestone Payment 56 Successfully Completes Phase 56 Product Designation 56 Potelligent Technology 56 RNAi Therapeutic 55 sNDA submission 55 balsalazide tablet 55 Receives Fast Track 55 Receives Approval From 55 KRYSTEXXA TM 55 ZEFTERA ™ 55 Glybera R 55 CombinatoRx Incorporated 55 Panzem R 55 SPRYCEL ® 55 NASDAQ INGN 55 Investigational Oral 55 Kissei Pharmaceutical 55 NasdaqGM SPPI 55 Increases Stock Repurchase 55 Marketing Authorization 55 Marketing Authorization Applications 55 OMP designation 55 Nasdaq CYCC Nasdaq CYCCP 55 oral methylnaltrexone 55 k premarket 55 Nasdaq VRTX 55 SPARLON 55 Taro Receives 55 Aloxi ® 55 Trelstar R 55 Orphan Drug 55 Synerx 55 IND Application 55 Arzerra TM 55 mesylate tablets approved 55 SCIB1 55 confirmatory pivotal 55 visit www.targanta.com 55 Orphan Designation 55 candidate brentuximab vedotin 55 website www.celsion.com 55 Emezine 55 Hematide ™ peginesatide 55 refractory chronic lymphocytic 55 PRECISE trial 55 Silodosin 55 subsidiaries visit http:/www.apricusbio.com 55 Somatuline R Depot 55 Australian Therapeutic Goods 55 Xyzal R 55 ANDA abbreviated 55 Inc. NASDAQ CVTX 55 candidate REP# 55 Regulatory Submissions 55 Xcytrin R 55 VISICOL R 55 Oral Calcitonin 55 Levoleucovorin 55 IV APAP 55 Nasdaq PGNX today 55 HuMax TAC 55 Subpart E 55 SIX RO ROG 55 Firazyr 55 OTC ZEGERID 55 Raptiva R 55 Icatibant 55 please visit www.middlebrookpharma.com 55 SinuNase ™ 55 Begin Clinical Trials 55 Romiplostim 55 Provider ASP 55 Announces Tentative Approval 55 Ventrus 55 Metformin HCl 55 zolpidem tartrate sublingual tablet 55 ISO Vorin TM 55 IND CTA 55 Delaying apoptosis may 54 Prodarsan R 54 visit http:/www.mannkindcorp.com 54 TRISENOX ® 54 Vulnerability Description Language 54 Evoltra TM 54 Camvia 54 SUCCEED trial 54 Trobalt 54 NASDAQ ARRY 54 Nivestim 54 BEMA Fentanyl 54 methylnaltrexone bromide 54 Fodosine 54 PDE4 inhibitor 54 HepeX B 54 apoptosis inducer 54 Phase lll 54 Presents Preclinical Data 54 Cloretazine ® 54 New Drug IND 54 Lamictal ODT 54 Iluvien ® 54 ZEGERID Capsules 54 NitroMist TM 54 Sunesis Pharma 54 severe hypercholesterolemia 54 Cand5 54 CERVARIX R 54 Seasonal Influenza Vaccine 54 proprietary transdermal patch 54 transmucosal delivery system 54 Gentamicin Surgical Implant 54 generation purine nucleoside 54 acyclovir Lauriad R 54 registrational studies 54 AMPAKINE CX# 54 Hsp# Inhibitor 54 Allovectin 7 54 Xenazine ® 54 Cellegesic 54 diagnostic molecular imaging 54 OTCBB HXBM developer 54 Diabetic Macular Edema 54 Phase Ib II 54 PROGENSA R 54 Nasdaq Delisting Notice 54 ANTEGREN 54 Pivotal Trial 54 PHASE III 54 tiapamil 54 naproxen esomeprazole magnesium 54 Market Approval PMA 54 Velaglucerase Alfa 54 testosterone gel LibiGel 54 ZALBIN 54 NASDAQ ENMD 54 Increases Stock Buyback 54 Solutions CVAS 54 Alnylam #x# 54 Stavzor 54 BRIM3 54 T Pred 54 NYSE Amex PTN 54 OTCBB PYTO 54 Explores Strategic Alternatives 54 Ranexa R 54 granted Ortec 54 orphan medicinal product 54 CHMP opinion 54 Paris IPN Euronext 54 Surfaxin lucinactant 54 targeted molecular radiotherapeutics 54 proprietary radiolabeled monoclonal 54 Pulmonary Arterial Hypertension 54 Antibody Drug Conjugate 54 Orphan Drug Status 54 CancerVax Corporation 54 Preotact R 54 Immunotherapeutic 54 Anti CD# Antibody 54 Patent Broadly Covering 54 Presents Positive 54 website http:/www.celsion.com 54 Evoltra 54 nasal calcitonin product 54 novel histone deacetylase 54 ALN PCS 54 Rotarix R 54 Frova ® 54 Nasdaq NPSP 54 commercialize AzaSite 54 ATPace TM 54 BioGlue Surgical Adhesive 54 Therapeutic Vaccine 54 Anturol TM 54 Thrombin topical Recombinant 54 Inc. NASDAQ ONTY 54 sBLA 54 AMD# [002] 54 FDA Orphan Drug 54 omacetaxine mepesuccinate 54 Loramyc ™ 54 Initiates Phase 2b 54 Morphine Sulfate 54 gastrointestinal disorders characterized 54 Oral Spray 54 PrevOnco 54 Testosterone MDTS ® 54 Omigard TM 54 LE SN# 54 Oracea TM 54 Pafuramidine 54 Combination REOLYSIN R 54 corticotropin injection 54 Intravenous Human 54 Nasdaq BCRX 54 Oral Insulin 54 Milestone Payments 54 Entereg alvimopan 54 OTCQX QRXPY 54 Plenaxis R 53 Evoltra ® 53 Orazol 53 Trofex 53 Reports Inducement Grants 53 Phase 2a Trial 53 HEPLISAV TM 53 Audited Financials 53 Soliris TM eculizumab 53 Zelrix 53 Glybera 53 IGXT IntelGenx today 53 PDUFA Prescription Drug 53 Urocidin TM 53 Drug Eluting Stent System 53 oral ridaforolimus 53 Breviary prayer book 53 Pegloticase 53 License Application 53 MKC# MKC# PP 53 Therapeutic Antibodies 53 Intermezzo ® NDA 53 Rhucin R 53 ZEVALIN ® 53 NASDAQ CXSP announced 53 Drug Submission 53 Velac 53 BioDelivery Sciences 53 SUTENT ® 53 ChemGenex Pharmaceuticals Limited 53 Inc. OTCBB SYBD 53 NASDAQ SMMX 53 Tibotec BVBA 53 Dalbavancin 53 TSX SHQ 53 evaluating mipomersen 53 iPS Cell 53 PANVAC VF 53 ENZON 53 histamine dihydrochloride 53 Receives Favorable 53 registrational 53 MarrowXpress 53 Licenses Novel 53 develop PS# 53 FOLOTYN ® 53 BioGlue R 53 Completes Enrollment 53 UPLYSO 53 Recombinant Human 53 Hexvix ® 53 Receives Conditional 53 GTC NASDAQ GTCB 53 Vion Pharmaceuticals 53 LibiGel NDA 53 Somatuline Depot 53 Tezampanel 53 Pre IND 53 Lenocta TM 53 Renvela ® 53 Tech DVAX 53 Ketotransdel 53 Freeze Drying 53 % uracil topical 53 NDA resubmission 53 Completes Patient Enrolment 53 CLIA waiver 53 ® decitabine 53 Oral BDP 53 refractory Hodgkin lymphoma 53 Phase 2b Clinical Trial 53 Auxilium Pharma 53 FDA Approves Expanded 53 Certican 53 OMNARIS HFA 53 NASDAQ NPSP 53 Flexpoint Announces 53 ZEGERID Chewable Tablets 53 novel oral anticoagulant 53 molecular imaging pharmaceuticals 53 TOCOSOL Paclitaxel 53 Phase IIb Clinical Trial 53 Meets Primary Endpoint 53 Keppra ® XR 53 REBETOL combination therapy 53 Hematological Malignancies 53 MK #B 53 initiate multicenter 53 Junovan TM 53 Phase 2a clinical trials 53 Dyloject TM 53 PD2i ® algorithm 53 Submits Revised 53 ImmunoCellular Therapeutics 53 Phase Ib IIa 53 initiate Phase 1b 53 POSIDUR TM ELADUR TM 53 Phase IIb trials 53 LEVADEX ™ 53 APF# NDA 53 Pandemic Influenza Vaccine 53 Zingo TM 53 ATPace 53 Loramyc 53 ALVESCO R 53 Entereg TM 53 Provisional Patent 53 DAYTRANA TM 53 Vicriviroc 53 Shire BioChem Inc. 53 Prolongs Survival 53 Pivotal Study 53 PAION AG 53 Orphan Drug status 53 DPX Survivac 53 recombinant biopharmaceutical 53 Testosterone Gel 53 Milestone Payment 53 TKM Ebola 53 Nasdaq OSCI 53 Announce Successful Completion 53 HepeX B TM 53 Solzira 53 METOZOLV ODT 53 Zidovudine Tablets 53 Zolpimist 53 Elagolix 53 OvaRex R 53 SUMAVEL 53 alvimopan 53 Nasdaq HALO 53 Inc. Nasdaq NEOL 53 serious systemic Staphylococcal 53 ENLIGHT 53 Inc NGSX 53 autologous cellular immunotherapy 53 FDA APPROVES 53 WILEX 53 Inc. Nasdaq IDMI 53 Hedgehog Pathway Inhibitor 53 HepaGam B 53 XIAPEX 53 faropenem medoxomil 53 Clinical Trial Results 53 Phase 1b Clinical Trial 53 Exalgo TM 53 Simulect 53 RECEPTORS LLC 53 Becomes Effective 53 GRAS notification 53 commercialize toremifene 53 GlaxoSmithKline Biologicals SA 53 SNS# T 53 Zenvia Phase III 53 Orapred ODT 53 Phase IIb Trial 53 R sipuleucel T 53 AgaNase 53 Celgene Thalomid 53 Ipsen Euronext IPN 53 Nicotine Conjugate Vaccine 53 Linjeta TM 53 PRN FDA Approves 53 Investigational 53 PI3K/Akt pathway inhibitor 53 Thelin TM 53 inhaled AAT 53 Uvidem 53 XL# anticancer compounds 53 Alvesco R 52 Gendux 52 Earns Milestone Payment 52 ViRexx Announces 52 IIa trial 52 Valtropin 52 Nycomed GmbH 52 THALOMID 52 Saforis 52 Accelerate Commercialization 52 XIAFLEX ™ 52 develop GED aPC 52 VitiGam 52 Vascular Disrupting Agent 52 visit www.genenews.com 52 Clinical Trial Evaluating 52 naronapride 52 Shonin 52 Allovectin 7 R 52 REGENERX BIOPHARMACEUTICALS INC. 52 VCRT 52 rxRNA 52 ANDA Abbreviated New 52 BEMA Granisetron 52 acyclovir Lauriad ® 52 Inc. Nasdaq CRTX 52 please visit www.medicinova.com 52 Nasdaq VNDA 52 Prostate Cancer Vaccine 52 Zegerid OTC 52 miconazole Lauriad R 52 HuCAL antibodies 52 ATryn R 52 Receives Stockholder Approval 52 ORBIT II 52 APNB 52 ALTROPANE R 52 NADiA ProsVue 52 PerClot 52 FDA Approvals 52 Project QTDP program 52 BLP# Liposome Vaccine 52 Transcept Pharmaceuticals 52 PIX# trial 52 TolerRx 52 Nasdaq Delisting 52 Filing Status 52 Orphan Drug Designation 52 Antibody Discovery 52 BTG plc 52 Sanvar R 52 OROS R Hydromorphone 52 Circ Pharma 52 Receives Marketing Authorization 52 Tyrosine Kinase Inhibitor 52 PHX# 52 intravenous acetaminophen 52 investigational humanized monoclonal antibody 52 Plicera 52 MicroThermX 52 Phase III Trial 52 Febuxostat 52 Systemic Delivery 52 ruxolitinib 52 License Option Agreement 52 Files Shelf Registration 52 eCTD format 52 Electronic Submission 52 Kiadis 52 CHMP Opinion 52 VaxImmune 52 Clinical Trial Application 52 Drug Candidate 52 STEDESA 52 application sNDA 52 Novel Antibiotic 52 Maribavir 52 Common Stock Repurchase 52 non nucleoside HCV 52 SmPC 52 Schizophrenia Drug 52 EDQM 52 Arzerra ofatumumab 52 Announce Early Termination 52 Zensana 52 PDX pralatrexate 52 Evoltra R 52 Combidex 52 Accelerated Assessment 52 Ercole Biotech 52 BYETTA ® 52 PROMUS Element Stent System 52 Nasdaq OPTR 52 Harry Palmin President 52 Patent Issued 52 UCB Pharma SA 52 Syntonix Pharmaceuticals 52 mitogen activated ERK kinase 52 Troxatyl TM 52 Horizant ™ 52 TRANSDUR ® 52 technology visit http:/www.genmab.com 52 NeutroPhase TM 52 OTCBB IMUC 52 Mylan Receives Approval 52 Product Monograph 52 sterile lidocaine patch 52 Advanced Melanoma 52 Increases Share Repurchase 52 Spiegelmer ® 52 Adopts Stockholder Rights 52 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 52 Aryplase 52 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 52 RainStorm 52 Initiated Phase 52 EVIZON TM 52 TRANSDUR Bupivacaine 52 Enters Beta 52 ORENCIA R 52 Nasdaq PCYC 52 Restanza TM 52 LibiGel ® 52 ELADUR ™ 52 Fibrin Sealant 52 investigational hepatitis B 52 lucinactant 52 Subpart H 52 CLIRS trial 52 Megapharm Ltd. 52 RESTORE CLI 52 Inc. NASDAQ HITK 52 AMEX RGN www.regenerx.com 52 Barr ANDA 52 Security Consortium WASC 52 candidate deforolimus 52 Expression Genetics 52 Commences Subsequent 52 CIMZIA r 52 Aganocide 52 ATryn ® GTC recombinant 52 Biologics License Applications 52 rALLy clinical trial 52 PROMACTA CARES 52 CyDex Pharmaceuticals 52 Eligard R 52 Commercialization Agreement 52 Oncoscience AG 52 Eucreas 52 Bendamustine 52 Loxapine 52 Silicon Dimensions 52 Omapro 52 FIRAZYR 52 dextromethorphan quinidine 52 Shelf Registration 52 PNP inhibitor 52 Staphylococcus aureus Polysaccharide Conjugate 52 non nucleoside inhibitor 52 Priority Review 52 Paragraph IV certifications 52 WILEX AG 52 valopicitabine NM# 52 Lupus Drug 52 Optimer Pharma 52 Adenuric R 52 Tostrex 52 lorcaserin NDA 52 Approvable 52 vapreotide acetate 52 Present Preclinical Data 52 Abstral ® 52 CryoSeal FS System 52 Enables Easy 52 seliciclib CYC# 52 LymphoStat B TM 52 anthrax monoclonal antibody 52 By JAMAAL ABDUL 52 Elan NanoCrystal 52 reslizumab 52 Miraculins Announces 52 OTC Zegerid 52 RNAi Therapeutics 52 novel trazodone formulation 52 EGRIFTA TM 52 JHP Pharmaceuticals LLC 52 indiplon capsules 52 FRDA 52 NASDAQ Listing 52 lexidronam injection 52 Chaim Lebovits President 52 Welichem 52 Ceplene ® histamine dihydrochloride 52 Sublicense 52 Phase III confirmatory 52 Keryx Biopharma 52 FACTIVE R gemifloxacin 52 DermTech International 52 ALN TTR 52 LidoPAIN SP 52 sarcoma melanoma 52 deforolimus 52 Patent Covering 52 Patents Upheld 52 Has Commenced 52 Entereg R 52 diarrhea predominant irritable 52 Archexin 52 Nasdaq CLDX 52 NYSE MRX 52 Inc.today announced 52 GALNS 51 Hedgehog antagonist 51 Pralatrexate 51 Xolegel 51 PLK1 SNALP 51 Pirfenidone 51 Bazedoxifene 51 Junovan 51 Recommends Approval 51 investigational oral hepatitis C 51 novel bactericidal 51 CLIA Waiver 51 Key Milestones 51 ACAPODENE R 51 ROTATEQ 51 Targretin capsules 51 Gout Drug 51 Biomarker Study 51 Inc. Nasdaq SEPR 51 MIST II 51 Praecis 51 elbion 51 Pruvel 51 including eniluracil ADH 51 initiate Phase 2a 51 Proquin 51 Kuvan TM sapropterin 51 Fytokem 51 Transkaryotic Therapies TKTX 51 rThrombin 51 Phase 1a clinical 51 SILENOR 51 var arrContent = 51 NASDAQ IDEV 51 Friedreich Ataxia FRDA 51 Troxatyl 51 Captisol ® 51 apricitabine ATC 51 Fortigel 51 Keppra ® levetiracetam 51 memantine HCl 51 Release Capsules 51 SAR# [004] 51 Lung Cancer Drug 51 APTIMA HPV assay 51 Exclusive License 51 RGRX 51 Milestone Payment From 51 ALN HPN 51 No Objection Letter 51 NYSE Amex Listing 51 FORADIL 51 include Phenoptin TM 51 Completes Previously Announced 51 RAPTIVA 51 MEND CABG II 51 GTC recombinant human 51 Visian Toric ICL 51 Fabry Disease 51 ATryn ® 51 DOV Pharmaceutical 51 Anavex #-# 51 orphan designation 51 Patent Reexamination 51 InvaGen 51 Metabasis stockholders 51 Japanese Encephalitis vaccine 51 radiation sensitizer 51 Nasdaq CRXL 51 Ceflatonin ® 51 Pivotal Phase II 51 Naglazyme R 51 Augment ™ 51 investigational antiplatelet agent 51 Rescula 51 Development OOPD 51 topical non steroidal 51 GetGoal Phase III 51 Clofarabine 51 PMA Supplement 51 HCl capsules 51 Rotavirus Vaccines 51 HCV polymerase 51 Orphan Drug designation 51 Occlusin TM 51 OmniWave 51 Firazyr ® 51 Exelixis logo 51 Phase 2b Trial 51 StaphVAX 51 NASDAQ Listing Qualification 51 Molecular Diagnostic Test 51 Cardioxyl Pharmaceuticals 51 Raptiva ® 51 Settle Patent Litigation 51 Bosutinib 51 molecular chaperone regulation 51 Complete Response 51 Shigamabs R 51 Generic Version 51 mertansine 51 GATTEX TM 51 Phase IIb clinical trials 51 Amlodipine Besylate Tablets 51 CRTX 51 FDA approvable letter 51 Geron telomerase technology 51 Phase III HEAT 51 Vaccinogen 51 InSight Publisher 51 Velcade bortezomib 51 bioFILM PA TM 51 EPCT 51 Actemra tocilizumab 51 JNJ Q2 51 Firdapse 51 Polymer Microspheres 51 pantoprazole sodium 51 PROSTASCINT R 51 IG HCR ;) CO 51 Ondansetron Injection 51 DIFICID ™ 51 Creditor Protection 51 Amigal TM 51 adecatumumab MT# 51 Nexavar ® 51 ZaBeCor 51 Lowers Q4 51 NASDAQ NVAX 51 ferumoxytol Injection 51 bazedoxifene 51 Pivotal Clinical Trial 51 Metformin GR 51 vinorelbine tartrate 51 Polyphenon ® E 51 Locteron exclusively 51 supplemental Biologics License 51 mGluR2 positive 51 Scientific Advice 51 Abbott Laboratories Depakote 51 peginesatide 51 Tarsa Therapeutics 51 Argatroban 51 concerning CombinatoRx 51 GATTEX ® 51 Sanctura XR 51 Impax Labs 51 ABL inhibitor 51 RIGScan 51 Cimzia TM 51 Cladribine Tablets 51 Dermylex TM 51 Preotact 51 leading oral taxane 51 Periostat R 51 Novel Oral 51 tezampanel NGX# 51 Alvesco ® 51 POSIDUR TM 51 Juvantia 51 ANDA submission 51 product candidate Lpathomab 51 Phenoptin 51 LO LOESTRIN FE 51 NASDAQ CRXL 51 Expands Scope 51 Nasdaq VICL 51 LION bioscience AG 51 Prestara 51 Alnylam Biotherapeutics 51 rasagiline tablets 51 ACUROX 51 Cleviprex TM clevidipine 51 Thalidomide Pharmion 51 faropenem 51 Prestara TM 51 TKB# 51 ZFP Therapeutics 51 successfully commercialize Silenor 51 forodesine 51 Avanir Pharma 51 please visit http:/www.atherogenics.com 51 Phase III TRIST 51 Exherin 51 ORE# 51 Oracea ® 51 Stimuvax R 51 Receives Patent 51 MAb therapy 51 sapropterin dihydrochloride 51 Pivotal Phase 51 GeoVax AIDS vaccine 51 SNT MC# 51 approvable letters 51 MelaFind ® 51 Listings Qualifications Panel 51 Telatinib 51 Nasdaq TRCA 51 Genentech Provides Update 51 RECOTHROM R 51 Remain Listed 51 Hold Second Quarter 51 Tarceva TM 51 confirmatory Phase 3 51 Solzira TM 51 AMITIZA ® 51 Crucell NV NYSE Euronext 51 Fast Track Designation 51 OVA1 TM 51 IXIARO ® 51 Wins Patent Infringement 51 PrevOnco ™ 51 LUVENIQ 51 KALBITOR ® 51 Protherics PLC 51 maribavir 51 Executes Definitive 51 vemurafenib 51 Lauriad 51 Seikagaku Corporation 51 Surgical Adhesive 51 sumatriptan succinate injection 51 alvespimycin 51 Collaborators Publish 51 polymer platinate 51 Inc. Nasdaq VVUS 51 ThermoDox R 51 Nasdaq PPHM 51 Complete Response Letter CRL